Real-world experience of using stereotactic radiotherapy combined with anti-vascular endothelial growth factor to treat neovascular AMD.
Rosalind C CreerNattapon BoonarphaGemma GouldAzita RajaiRamandeep ChhabraPublished in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2024)
A therapy combining SRT with IVI has shown an overall reduction in the number of injections required in nAMD patients at 12, 24, and 36 months following SRT compared to IVI treatment alone. These real-world outcomes are comparable to other studies while also confirming the maintenance of the reduced frequency of required IVI for patients with nAMD.
Keyphrases
- vascular endothelial growth factor
- age related macular degeneration
- endothelial cells
- early stage
- radiation therapy
- locally advanced
- radiation induced
- type diabetes
- squamous cell carcinoma
- small cell lung cancer
- mesenchymal stem cells
- ultrasound guided
- case control
- brain metastases
- bone marrow
- replacement therapy
- cell therapy